HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/7/2020)... ... 07, 2020 , ... Dr. Louis M. DeJoseph is proud to ... scalp health. It is now possible to receive Keravive treatments from HydraFacial at the ... Dr. DeJoseph is able to provide clients with the best services to help them ...
(Date:7/4/2020)... ... July 03, 2020 , ... Houston Life coach, Rashad Garrett, has ... beyond with the launch of his new app, Faith Of A Mustard Seed (FOAMS). ... dealing with mental health issues. In fact, a Federal Agency emergency helpline dedicated to ...
(Date:7/2/2020)... ... July 02, 2020 , ... Columbia ... Professional of the Year Award to Eric Simmons of Temecula, California. , ... nominations. Simmons, who holds a master’s degree in occupational safety and health from ...
(Date:7/1/2020)... ... July 01, 2020 , ... ABSTRAX, an industry leader in ... new terpene infused product line including custom rolling papers, cones, flat wraps, ... profiles and flavors worldwide. , “We’ve made it easier than ever for brands ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... ... call for participation in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American ... Tubs, and Catch Basins. PHTA is seeking member participation on the PHTA-7 Standard ...
Breaking Medicine News(10 mins):
(Date:6/28/2020)... ... June 26, 2020 , ... ... The campaign brings together patients, healthcare providers, advocates, and scientists to spread awareness ... treatment for these devastating respiratory conditions. , More than 35 million ...
(Date:6/25/2020)... (PRWEB) , ... June 25, 2020 , ... ... leading industry analysts Top App Developers & DesignRush following the launch a recent ... first comprehensive exercise/community platform for cancer survivors. , Commissioned by MyVictory ...
(Date:6/25/2020)... ... June 25, 2020 , ... Air Date: 22 ... https://www.voiceamerica.com/episode/124183/immunity-protector-with-natures-tears-eyemist , “Eyes are our number one sensory input,” says Philip ... iTunes. “Being able to see clearly is being able to receive information you ...
Breaking Medicine Technology:
Cached News: